Your browser is no longer supported. Please, upgrade your browser.
Kintara Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.11 Insider Own0.10% Shs Outstand29.27M Perf Week-37.14%
Market Cap36.50M Forward P/E- EPS next Y-0.17 Insider Trans0.00% Shs Float28.97M Perf Month-39.31%
Income-38.60M PEG- EPS next Q-0.21 Inst Own8.40% Short Float3.61% Perf Quarter-63.03%
Sales- P/S- EPS this Y72.30% Inst Trans17.50% Short Ratio1.47 Perf Half Y-53.44%
Book/sh-0.12 P/B- EPS next Y57.50% ROA-236.00% Target Price- Perf Year-34.33%
Cash/sh0.38 P/C2.32 EPS next 5Y- ROE- 52W Range1.06 - 3.35 Perf YTD-31.25%
Dividend- P/FCF- EPS past 5Y28.20% ROI- 52W High-73.73% Beta1.58
Dividend %- Quick Ratio6.50 Sales past 5Y- Gross Margin- 52W Low-16.98% ATR0.11
Employees4 Current Ratio6.50 Sales Q/Q- Oper. Margin- RSI (14)18.95 Volatility15.52% 7.64%
OptionableNo Debt/Eq- EPS Q/Q-32.30% Profit Margin- Rel Volume10.78 Prev Close1.12
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume709.65K Price0.88
Recom2.00 SMA20-37.81% SMA50-41.14% SMA200-47.76% Volume7,649,590 Change-21.43%
Sep-24-21 08:00AM  
Sep-22-21 12:30PM  
Aug-17-21 08:00AM  
Aug-12-21 08:00AM  
Aug-06-21 10:20AM  
Aug-04-21 08:00AM  
Jul-09-21 06:29AM  
Jul-07-21 12:56PM  
Jul-01-21 01:36PM  
Jun-13-21 10:20PM  
Jun-07-21 08:00AM  
Jun-03-21 08:00AM  
Jun-02-21 08:00AM  
May-26-21 12:25PM  
May-14-21 08:00AM  
May-11-21 07:00AM  
May-05-21 08:00AM  
May-04-21 08:00AM  
Apr-12-21 08:00AM  
Apr-05-21 10:51AM  
Mar-17-21 08:00AM  
Mar-10-21 08:00AM  
Mar-03-21 08:00AM  
Mar-02-21 08:00AM  
Mar-01-21 05:36AM  
Feb-17-21 08:00AM  
Feb-12-21 08:30AM  
Feb-08-21 05:25AM  
Jan-13-21 08:00AM  
Jan-06-21 01:00PM  
Jan-05-21 08:00AM  
Dec-03-20 08:30AM  
Dec-01-20 04:47AM  
Nov-30-20 07:44AM  
Nov-19-20 08:00AM  
Nov-13-20 08:00AM  
Oct-21-20 08:00AM  
Oct-12-20 06:45AM  
Oct-01-20 03:30PM  
Sep-21-20 08:30AM  
Sep-16-20 11:54AM  
Sep-01-20 08:30AM  
Aug-31-20 05:00PM  
Aug-26-20 08:30AM  
Aug-25-20 08:30AM  
Aug-21-20 08:15AM  
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.